Acumen Pharmaceuticals (ABOS) Receivables - Other (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Receivables - Other of $772000.0 in Q1 2026, up 23.52% quarter-over-quarter from $625000.0 in Q4 2025, and up 105.32% year-over-year from $376000.0 in Q1 2025.
Acumen Pharmaceuticals' Receivables - Other history runs 6 years deep, the most recent figure standing at $772000.0 for Q1 2026.
- In Q1 2026, Receivables - Other rose 105.32% year-over-year to $772000.0; the TTM figure through Mar 2026 stood at $772000.0 (up 105.32% YoY), while the FY2025 annual figure was $625000.0, up 81.16% from the prior year.
- Receivables - Other came in at $772000.0 for Q1 2026 at Acumen Pharmaceuticals, up from $625000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $772000.0 in Q1 2026 to a low of $106000.0 in Q2 2024.
- A 4-year average of $360000.0 and a median of $330000.0 in 2024 frame the typical range for Receivables - Other.
- On a YoY basis, Receivables - Other climbed as much as 197.17% in 2025 and fell as far as 41.42% in 2025.
- Acumen Pharmaceuticals' Receivables - Other stood at $225000.0 in 2023, then jumped by 53.33% to $345000.0 in 2024, then surged by 81.16% to $625000.0 in 2025, then gained by 23.52% to $772000.0 in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $772000.0, $625000.0, and $379000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 772,000.00 |
| Mar 31, 2026 | 772,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Sep 30, 2025 | 379,000.00 |
| Sep 30, 2025 | 379,000.00 |
| Jun 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 315,000.00 |
| Mar 31, 2025 | 376,000.00 |
| Mar 31, 2025 | 376,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Dec 31, 2024 | 345,000.00 |
| Sep 30, 2024 | 268,000.00 |
| Sep 30, 2024 | 268,000.00 |
| Jun 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 106,000.00 |
| Mar 31, 2024 | 189,000.00 |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | 225,000.00 |
| Dec 31, 2023 | 225,000.00 |
| Sep 30, 2021 | 109,000.00 |
| Sep 30, 2021 | 109,000.00 |
| Jun 30, 2021 | 109,000.00 |
| Jun 30, 2021 | 109,000.00 |
| Dec 31, 2020 | 109,000.00 |
| Dec 31, 2020 | 109,000.00 |